“Basically, the responses were, ‘What can we do to help you?'” Dan Liljenquist, senior vice president and chief strategy officer of Salt Lake City-based Intermountain Healthcare told STAT.
The collaboration of seven major health system will begin by manufacturing 14 hospital-administered generic drugs that have been in short supply.
Interest from those regulators mirrors the Trump administration’s focus on bringing down drug prices and improving drug shortages.
But after meeting with the regulators, Mr. Liljenquist said the company doesn’t have much to ask for from the FDA or Capitol Hill.
“We said, look: Just apply the same rules you apply to everybody else to us, and that’s all we need,” Mr. Liljenquist told STAT. “We are not looking to Washington to solve this issue.”
Read the full report here.
More articles on pharmacy:
20 generic drugmakers must answer price-fixing lawsuit
Novartis strikes $2.1B deal to buy cancer drugmaker Endocyte
Insys tactics to hike fentanyl sales detailed in Missouri senator’s report
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.